Innocent lives lost and saved: the importance of blood transfusion for children in sub-Saharan Africa by Walter H Dzik
Medicine for Global Health
Dzik BMC Medicine  (2015) 13:22 
DOI 10.1186/s12916-014-0248-5COMMENTARY Open AccessInnocent lives lost and saved: the importance of
blood transfusion for children in sub-Saharan
Africa
Walter H DzikAbstract
Severe anemia in children is a leading indication for blood transfusion worldwide. Severe anemia, defined by the
World Health Organization as a hemoglobin level <5 g/dL, is particularly common throughout sub-Saharan Africa.
Analysis of data from the Fluid Expansion as Supportive Therapy (FEAST) trial offers new insights into the
importance of blood transfusion for children with severe anemia. The principal findings of this analysis include the
observations that life-threatening anemia in children is a frequent presenting condition in East Africa; that delays in
transfusion therapy are lethal; and that inadequate transfusion is probably more common than currently recognized.
The findings of this new study highlight the need for changes in blood inventory management in sub-Saharan
hospitals and the need for more research on transfusion therapy for children in peril.
Please see related article: http://dx.doi.org/10.1186/s12916-014-0246-7
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In sub-Saharan Africa (SSA), the death of a child is an
everyday tragedy. The sorrow is compounded by the fact
that most children die not as a result of complex con-
genital abnormalities, from malignancy, or from chronic
incurable diseases, but rather from completely treatable
and reversible conditions such as severe malarial anemia.
Simply stated, blood transfusion therapy for children in
SSA is a matter of life and death.
In recent years, national blood transfusion programs
in SSA have made steady and significant progress [1].
Supported by government financing and through external
aid from programs such as the President’s Emergency Plan
for AIDS Relief (PEPFAR), national initiatives for vol-
unteer donor blood collection, viral testing, and distri-
bution to hospitals continue to advance. Nevertheless,
even in well-run programs, supply falls short of demand,
and blood donations per 1,000 citizens in low-income
countries are far below that seen in wealthy nations [2].
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care and to treat the burden of trauma brought on by in-
creasing road traffic accidents, burns from open fires, and
human violence [3]. Nevertheless, children with severe
anemia remain one of the most important categories
for blood transfusion in SSA, and high-quality informa-
tion focused on pediatric blood transfusion is both use-
ful and welcome.
In a research article published in BMC Medicine,
Sarah Kiguli and colleagues present an important and
data-rich report from East Africa that details the use and
the outcomes of blood transfusion in children [4]. The
report analyzes data from the Fluid Expansion as Sup-
portive Therapy (FEAST) trial, which is a previously pub-
lished randomized controlled trial of volume loading in
children who presented with severe febrile illness to six
hospitals in three East African nations during the period
2009 to 2011 [5]. Enrollment required that children ex-
hibit respiratory distress or impaired consciousness plus
signs of impaired tissue perfusion. As a result, the FEAST
trial focused on very sick children presenting for emer-
gency care, and this is reflected by the fact that, overall,n Open Access article distributed under the terms of the Creative Commons
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first 48 hours.
What are the main findings of this new report?
While there are many lessons in the data, readers will
want to take away three major findings.
Life-threatening anemia in sick children is extremely
common
Hemoglobin testing was done on presentation to hos-
pital for over 3,000 children who met enrollment cri-
teria for the FEAST trial. Among these, a staggering 33%
were severely anemic, defined as having a hemoglobin
level <5 g/dL. In the majority of cases the anemia was a
consequence of malaria and thus completely correctable
with appropriate therapy. Indeed, severe anemia is the
most common of three major sub-syndromes of acute
P. falciparum malaria and when accompanied by lactic
acidosis is highly associated with a fatal outcome [6].
The robust data set reported by Kiguli et al. provides the
best measure to date of the magnitude of life-threatening
anemia in children presenting to hospitals in East Africa.
Any delay in blood transfusion is lethal
The single most striking finding of Kiguli et al. is the ab-
solute urgency of severe anemia in children. Consider
the following data taken from this report: Among children
with only moderate anemia (hemoglobin 5 to 7 g/dL),
those transfused within 8 hours of arrival had a 5% mor-
tality which was not different from the 4% mortality of
those transfused after 8 hours. However, among children
presenting with severe anemia (hemoglobin <5 g/dL), the
mortality among those transfused within 8 hours of arrival
was also 4%, but the mortality among those for whom
transfusion was delayed by more than 8 hours was 52%.
Indeed, 90% of these deaths occurred within just 2.5 hours
of arrival, and 100% of the deaths were within the first five
hours.
Inadequate transfusion (under-treatment) is probably
common
Given the limited blood resources throughout SSA, cur-
rent guidelines focus on transfusion support for the most
severely anemic individuals and recommend 10 mL/kg of
packed red blood cells (or 20 mL/kg of whole blood).
While these guidelines conserve use of a precious re-
source, they also likely leave a substantial number of chil-
dren in a condition of relative under-treatment. In the
report of Kiguli et al., nearly one-quarter of the children
who received an initial transfusion according to guidelines
ultimately received additional transfusions. Not surpris-
ingly, these repeat transfusions were associated with those
who presented with the most profound levels of anemia,
with extreme tachycardia, or in coma suggesting that thecurrent standard is not a sufficient dose for those at great-
est clinical risk.
Unanswered questions and next steps
The work of Kiguli et al. presents disturbing and pro-
vocative information on the number of innocent lives
lost to anemia in SSA. The findings also point the way
towards achieving better outcomes. The data presented
likely underestimate the tragedy of insufficient transfusion
support, because there are no published accounts of the
frequency with which urgent requests for blood go un-
filled for lack of supply - especially in more remote regions
of SSA. Nevertheless, for children with severe anemia, this
study reminds us, with substantial data, that children are
adaptive but are not invincible. Given the findings regard-
ing the high prevalence of severe anemia and the lethal
consequences resulting from delays in transfusion, we
now have the most robust data yet published to argue
convincingly for a resetting of goals for blood stocks
throughout the malarial regions of SSA. Safe blood should
not be a treatment rationed for life-threatening physiology
nor procured at the time of need, but rather must be avail-
able on site. In fact, a reserve of emergency Group O
packed red cells is standard in hospitals of all wealthy na-
tions and needs to become a target goal for SSA.
For the far larger population of children with moder-
ate anemia, the report of Kiguli et al. demonstrates the
current uncertainties of treatment that translate directly
into a wide variation in transfusion practice. What is
needed for these children is more clinical research that
will identify which children are in need of transfusion,
what the proper dose should be, and what the target goal
of therapy is - how much transfusion is appropriate.
Such research will be of substantial value to the great
number of children in SSA with sickle cell disease or
nutritional anemia who are likely to be underserved by
current transfusion practice.
An available supply of safe blood represents a fun-
damental healthcare infrastructure. Efforts underway in
SSA to organize national volunteer donor programs and
to promote professionals in transfusion medicine should
be supported [7]. Research designed to document the
safety and efficacy of stored blood, such as the Transfusion
in Severe Anemia with Lactic Acidosis trial [8], will be
of great value towards promoting an adequate blood
supply. Perhaps most importantly, all parties - govern-
ment, funding agencies, national blood transfusion ser-
vices, clinicians, religious groups, the media, and the
general public - need to reject complacency with the
status quo. Only then will innocent lives, stricken with
a fully treatable condition, continue to be rescued.
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